Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Core Insights - Eterna Therapeutics is advancing its induced mesenchymal stem cell (iMSC) therapy programs for treating advanced solid tumors and autoimmune diseases, with a successful inaugural meeting of its Scientific Advisory Board focusing on preclinical advances and clinical trial roadmaps [1][2][3] Company Overview - Eterna Therapeutics (Nasdaq: ERNA) specializes in innovative cell therapies, particularly through engineering induced pluripotent stem cells (iPSCs) into iMSCs, offering scalable, off-the-shelf treatment solutions without the need for patient-specific cell harvesting [4] Product Development - The company is developing two lead products: ERNA-101, aimed at activating the immune system to target cancer cells, and ERNA-102, designed to address inflammation in autoimmune diseases, with a primary focus on ovarian cancer for ERNA-101 [5][8] Scientific Advisory Board Insights - The Scientific Advisory Board includes leading experts who engaged in discussions about advancing next-generation cell therapies, emphasizing the importance of scientific rigor and innovation [2][7] - Highlights from the meeting included positive preclinical data for ERNA-101, strategies for optimizing dosage and administration routes, and potential combination therapies with CAR-T therapy and other immunomodulatory approaches [8] Future Directions - Eterna plans to continue collaboration with the Scientific Advisory Board and stakeholders to translate innovative therapies into clinical practice, with a focus on rigorous quality, safety, and efficacy criteria [3][8]